Clinical Trials
64 trialsPan Tumor Rollover Study
Bristol-Myers Squibb
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Parabilis Medicines, Inc.
EGRET
AstraZeneca
Spotlight
Astellas Pharma Inc
LUCERNA
Astellas Pharma Inc
GRACIE
UNICANCER
A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
Tyligand Pharmaceuticals (Suzhou) Limited
A Study of ASP3082 in Adults With Advanced Solid Tumors
Astellas Pharma Inc
ILUSTRO
Astellas Pharma Inc
Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer
M.D. Anderson Cancer Center
METIMMOX
University Hospital, Akershus
A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors
GlaxoSmithKline
Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab
AbbVie
IROCAS
UNICANCER
DisTinGuish
Leap Therapeutics, Inc.
A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Jazz Pharmaceuticals
A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer
NuCana plc
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
Pfizer
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
NuCana plc
OSCAR
Federation Francophone de Cancerologie Digestive
Postoperative Chemotherapy in High-Grade Appendiceal Adenocarcinoma With Peritoneal Carcinomatosis
University of California, San Diego
MK-4280-001
Merck Sharp & Dohme LLC
OCTASUR
Ukrainian Society of Clinical Oncology
NET02
The Christie NHS Foundation Trust
HIGH-LIGHT
Federation Francophone de Cancerologie Digestive
CanStem303C
Sumitomo Pharma America, Inc.
Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols
Sumitomo Pharma America, Inc.
Isolated Hepatic Perfusion With Melphalan Followed By Chemotherapy in Treating Patients With Unresectable Colorectal Cancer That is Metastatic to the Liver
National Institutes of Health Clinical Center (CC)
Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine")
Medical College of Wisconsin
Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors
University of California, San Francisco
Trybeca-1
ERYtech Pharma
Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)
EMD Serono
A Phase II Study of Neoadjuvant FOLFIRINOX
Indiana University
PEN-866 in Patients With Advanced Solid Malignancies
Tarveda Therapeutics
Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors
Genentech, Inc.
A Pilot Study of Pre- and Post-surgery Chemotherapy With mFOLFIRINOX in Localized, Resectable Pancreatic Adenocarcinoma
Endeavor Health
A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and Bevacizumab
AbbVie
A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer
Eli Lilly and Company
Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors
Bristol-Myers Squibb
Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Gilead Sciences
Study of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer
Oncolytics Biotech
SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial
Amgen
Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma
Oncolytics Biotech
Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)
Merck Sharp & Dohme LLC
Molecularly Tailored Therapy for Pancreas Cancer
Georgetown University
A Phase II Study of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer
Sanofi
Adjuvant Therapy(3 vs. 6 Months) With the FOLFOX 4 or XELOX for Stage II or Stage III Colon Cancer
Hellenic Oncology Research Group
FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma
University of California, San Francisco
DOUBLIRI
GERCOR - Multidisciplinary Oncology Cooperative Group